Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://bocx.realpennies.com
BioCurex (OTCBB: BOCX) continues to issue positive news this week. Yesterday, Jan. 14th 2008, at the open, Ken Weiner, publisher of Shazamstocks, announced profile coverage of BioCurex (http://biz.yahoo.com/pz/080114/134226.html)
They also recently released a press release states that more than three years of testing by BioCurex has confirmed RECAF's high degree of clinical sensitivity and specificity in detecting various types of cancer, even when the disease is at its earliest stage. RECAF (the receptor for alpha-fetoprotein) is a wide-spectrum marker present in malignant cancer cells and absent in most normal cells, allowing it to play a major role in the development of new diagnostic tests for prostate, breast, colorectal, lung and other cancers.
Under terms of the license agreement, Inverness Medical Innovations will obtain semi-exclusive worldwide rights to commercialize products using this technology. BioCurex will be paid up-front fees, product and development milestones plus royalties on product sales.
According to the World Health Organization, more than 10 million people are diagnosed with cancer every year, and this number is expected to reach 15 million in a dozen years. The RECAF technology becomes hugely significant when considering that the chance of a cure increases substantially if the disease is detected early (i.e. the five-year survival rate for breast cancer ranges from 87% at Stage 1 to only 13% at Stage IV). Cancer screening and recurrent evaluations are anticipated diagnostic applications for the RECAF cancer marker.
''BioCurex's RECAF technology has the potential to revolutionize cancer detection by differentiating malignant cells from healthy ones. For this reason, we are delighted to be partnering with one of the world's leading developer/manufacturers of advanced diagnostic products. With major facilities in the U.S., Europe and Asia, Inverness Medical Innovations has an impressive reputation for aggressive and innovative consumer marketing. We are especially looking forward to be working with them on expanding and implementing our RECAF technology on future cancer tests,'' said Ricardo Moro, M.D., BioCurex's CEO.
“Yesterday the stock closed at 0.68”.
Read our full disclaimer at: http://bocx.realpennies.com
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Never invest in any stock featured on the RealPennies.com website or email alerts unless you can afford to lose your entire investment. RealPennies.com is not a registered investment advisor, financial analyst, or broker. The information provided is obtained from sources deemed reliable, but RealPennies.com does not guarantee in any way the accuracy or completeness of such information made here. RealPennies.com affiliates, and friends and family may have a position in such securities. The position may have been acquired prior to the publication of this email. You should also be aware that the aforementioned parties do have the right to sell their positions at anytime without further notification. Any opinions expressed are subject to change without notice. RealPennies.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. We were compensated 15,000 cash for one month of coverage on BOCX. All information featured here is provided by the companies profiled, or is available from public sources and RealPennies.com makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Read our full disclaimer at: http://www.realpennies.com/content/view/19/36/
Sitemap: http://www.realpennies.com/sitemap.html
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment